Thalassemia: Causes, Treatment Options and Long-Term Health Outcomes

Makenzie Greene (Editor)

Series: Public Health in the 21st Century
BISAC: MED022000

Clear

$230.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Thalassemia is one of the most common genetic disorders worldwide and presents major public health and social challenges in areas of high incidence. The frequency of this disorder varies considerably with geographic locations and racial groups. Thalassemia refers to a group of inherited hemolytic anemia disorders that involve defects in the synthesis of hemoglobin α- or β-polypeptide chains. It leads to decreased hemoglobin production and hypochromic microcytic anemia associated with erythrocyte dysplasia and destruction.

Homozygous β-thalassemia (also known as thalassemia major, Cooley’s anemia, or Mediterranean anemia) is associated with the most severe signs and symptoms. Thalassemia major (TM) is a life-threatening condition that commonly manifests during early infancy, after which progressive pallor, severe anemia, and failure to thrive are common. Children with TM often develop feeding problems, recurrent fever, bleeding tendencies (especially epistaxis), susceptibility to infection, pathologic fractures of long bones and vertebrae, endocrine abnormalities, splenomegaly, lack of sexual maturation, and growth retardation. This book discusses cures and treatments available for thalassemia, as well as the causes and the type of long-term health outcomes it may cause. (Imprint: Nova Biomedical )

Preface

Chapter 1 - Cure of Thalassemia Major Using Related and Unrelated Donor Cord Blood Stem Cell Transplantation (pp. 1-36)
Lawrence D. Petz, M.D., John Chow, M.D., Ph.D., Tracie Dang, Andrew Song, Liang Liang, Michelle Chow, Christine Chow, Elizabeth Rao, Tang-Her Jaing, M.D. and Robert Chow, M.D., A.M. (StemCyte, Inc., Covina, California, USA, and others)

Chapter 2 - The Differential Diagnosis of Microcytosis (pp. 37-56)
Eloísa Urrechaga Igartua, Silvia Izquierdo Álvarez and Jesús Fernando Escanero Marcén (Laboratory. Hospital Galdakao – Usansolo, Galdakao, Vizcaya, Spain, and others)

Chapter 3 - Computer Aided Diagnosis of Thalassaemias: An Overview (pp. 57-70)
Giovanni Luca Masala and Bruno Golosio (POLCOMING Department, Section of Engineering and Information Technologies, University of Sassari, Viale Mancini, Sassari, Italy)

Chapter 4 - Hematopietic Stem Cell Transplantation for Thalassemia, Price and Prejudice (pp. 71-82)
Lawrence Faulkner, M.D. (Medical Coordinator Cure2Children Foundation, Florence, Italy)

Chapter 5 - Screening and Genotyping of Beta Thalassemia (pp. 83-122)
Sandra Stella Lazarte, María Eugenia Mónaco and Blanca Alicia Issé (Professor Cátedra Bioquímica Clínica I. Facultad de Bioquímica, Química y Farmacia. Universidad Nacional de Tucumán, Argentina, and others)

Chapter 6 - Molecular Therapies for Treatment of Thalassemia (pp. 123-134)
Eleni Papanikolaou (Laboratory of Biology, University of Athens School of Medicine, Athens, Greece)

Chapter 7 - Developments in the Molecular Diagnosis of Beta-Thalassaemia (pp. 135-154)
Sherry S. Y. Ho, Angela N. Barrett, Mahesh Choolani and Evelyn S. C. Koay (Departments of Laboratory Medicine, Molecular Diagnosis Centre, National University Hospital, Singapore, and others)

Chapter 8 Antioxidant Therapies for Thalassemia (pp. 155-174)
Ruchaneekorn W. Kalpravidh and Suneerat Hatairaktham (Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand)

Chapter 9 - Calcifications in Thalassemia: An Important Complication (pp. 175-178)
Somsri Wiwanitkit and Viroj Wiwanitkit (Wiwanitkit House, Bangkhae, Bangkok Thailand, and others)

Chapter 10 - Multi-Target Therapeutic Modalities for -Hemoglobinopathies (pp. 179-200)
Eitan Fibach (Department of Hematology, Hadassah – Hebrew University Medical Center, Jerusalem, Israel)

Chapter 11 - Assessing Services for Haemoglobin Disorders: A Toolkit for Service Planning (pp. 201-210)
Michael Angastiniotis and Androulla Eleftheriou (Thalassaemia International Federation, Nicosia, Cyprus)

Chapter 12 - Beta Thalasemia in Bahrain: An Overview (pp. 211-234)
Shaikha Al Arrayed (Chairperson of Genetic Department, Chairperson of Bahrain National Hereditary anemia Society, Genetic Department
Ministry of Health, Kingdom of Bahrain)

Chapter 13 - Dental and Orofacial Changes in Thalassemia Major: An Overview (pp. 235-248)
Faiez N. Hattab, B.D.S., Ph.D., Odont. Dr. (Amman, Jordan)

Index

You have not viewed any product yet.